PTX3 and cutaneous mastocytosis: Furthermore, we demonstrated that PTX3 and sTWEAK are elevated in CM patients and that high plasma levels of PTX3 can predict a good response to OnabotulinumtoxinA (OnabotA), which is widely used for the treatment of CM [18].